TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

Clin Otolaryngol. 2012; 37 (4): 276-282. 10. Laidlaw TM, et al. Chronic Rhinosinusitis with nasal polyps and asthma. J ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

Amgen and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial ...

The co-primary endpoints were change from baseline in total nasal polyp size (measured by endoscopic total Nasal ... name Tezspire ® for the add-on maintenance treatment of severe asthma in adult and ...

Advancing Phase 2 clinical trials of verekitug in patients with severe asthma and CRSwNP –– Commenced startup for a Phase 2 clinical trial in ...

Rheumatoid arthritis is an independent risk factor for CRSwNP recurrence after surgery, linked to higher tissue eosinophil counts, according to a recent study.

A study published in Frontiers in Medicine reveals that chronic rhinosinusitis with and without nasal polyps is closely correlated with asthma.A study was done to investigate the ...

For people with allergies, ongoing exposure to triggers may create a cycle of inflammation that contributes to polyp ...